Key statistics dashboard for Belite Bio, Inc (BLTE). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily.
Stock Data
| Price | $169.21 |
| Market Cap | $6.8B |
| Beta | -1.22 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -61.31 |
| Price / Book | 8.75 |
| P/S | 0.00 |
| P/FCF | -642128.02 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 33.56 |
| Quick Ratio | 33.56 |
| Cash Ratio | 0.00 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 319.70 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 19.33 |
| Cash per share | 0.00 |
| FCF per share | -0.00 |
| Tangible Book Value per share | 19.33 |
| Dividend per share | 0.00 |
Related companies: ACAD · ADMA · ARQT · CRNX · DYN · LGND · MIRM
Explore sector: Healthcare · Biotechnology
More sections of BLTE: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks